IGC Pharma (IGC) AI Stock Analysis

• Market Cap: $27.69M
• Dividend Yield: N/A
• Average Volume (3M): 715.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: -6.51%
• EPS Growth: 58.31%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 95,818,020
• 10 Day Avg. Volume: 826,885
• 30 Day Avg. Volume: 715,709
• PEG Ratio: 0.05
• Price to Book (P/B): 3.45
• Price to Sales (P/S): 17.16
• P/FCF Ratio: -4.13
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 23.96
• Enterprise Value/Gross Profit: 51.86
• Enterprise Value/Ebitda: -4.11
• 1Y Price Target: $5.00
• Price Target Upside: 1566.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.08
• Revenue Forecast (FY): $1.05M

• Rating: 47 Neutral
• Price Target: $0.29 ▼(-4.67% Downside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is primarily held down by weak financial performance—declining revenue and sustained losses—despite low leverage and some cash-flow improvement. Technical indicators are slightly supportive in the near term, while valuation is constrained by negative earnings. Recent financing helps liquidity but introduces additional capital-structure risk.

Positive Factors

Low leverage

A debt-to-equity ratio of 0.033 indicates conservative financial leverage, lowering fixed financing costs and bankruptcy risk. For a clinical-stage biotech with recurring R&D needs, low leverage preserves optionality to fund trials or pursue partnerships without large interest burdens over the next several months.

Improving free cash flow growth

A 22.83% TTM improvement in free cash flow growth signals better cash management and operational efficiency. Though absolute cash flows remain negative, improving FCF trends can extend runway and make future financing or strategic collaborations less dilutive if the company continues to convert R&D spending into controlled cash burn.

Access to capital for clinical R&D

Successful completion of a registered direct equity offering to raise ~ $234k demonstrates investor willingness to fund ongoing clinical programs. For a clinical-stage company, repeatable access to capital is a structural enabler, allowing continued trials and R&D execution to advance the pipeline toward value-driving milestones.

Negative Factors

Declining revenue trend

A 16.65% decline in TTM revenue reflects weakening top-line performance that undermines the firm's ability to self-fund development. For a company without broad commercial products, declining revenue increases dependence on external financing and makes multi-quarter R&D planning and hiring more fragile.

Sustained losses and negative margins

Deeply negative net margins and negative EBIT/EBITDA indicate persistent unprofitability. Over time, sustained operating losses erode equity, limit reinvestment capacity, and heighten the need for dilutive financings or costly debt, constraining strategic flexibility and long-term scale-up prospects.

Dilution and capital‑structure risk

Convertible promissory note terms (conversion on default at a 25% discount) plus an increase in authorized shares to 600M materially raise dilution risk. Repeated equity or contingent conversions can weaken shareholder claims, complicate governance, and make future financings more dilutive, pressuring per‑share economics.

IGC Pharma Business Overview & Revenue Model

Company Description

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

How the Company Makes Money

null

IGC Pharma Financial Statement Overview

Summary

Weak profitability and revenue trend (TTM revenue down 16.65% with deeply negative margins), partially offset by low leverage (debt-to-equity 0.033) and improving free cash flow growth (22.83% TTM) despite negative operating and free cash flow.

Income Statement

IGC Pharma's income statement reveals significant challenges, with declining revenue and negative profit margins. The TTM data shows a revenue decline of 16.65%, and the net profit margin is deeply negative at -4.78%. The company struggles with profitability, as evidenced by negative EBIT and EBITDA margins. Despite these challenges, the gross profit margin remains relatively stable, indicating some efficiency in cost management.

Balance Sheet

The balance sheet indicates a low debt-to-equity ratio of 0.033, suggesting conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated but appears stable given the low debt levels. Overall, the balance sheet shows financial stability but lacks profitability.

Cash Flow

Cash flow analysis shows a positive trend in free cash flow growth at 22.83% TTM, indicating improved cash management. However, both operating and free cash flows remain negative, with a high operating cash flow to net income ratio of -2.58, reflecting cash flow challenges. The company maintains a positive free cash flow to net income ratio, suggesting some ability to cover losses with cash flow.

Breakdown	TTM	Mar 2025	Mar 2024	Jun 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.11M	1.27M	1.34M	911.00K	397.00K	898.00K
Gross Profit	511.00K	619.00K	733.00K	-158.00K	194.00K	-349.00K
EBITDA	-6.45M	-6.83M	-9.16M	-10.85M	-14.37M	-8.33M
Net Income	-6.45M	-7.12M	-13.00M	-11.51M	-15.02M	-8.81M
Balance Sheet
Total Assets	9.74M	8.75M	9.90M	17.18M	26.83M	35.87M
Cash, Cash Equivalents and Short-Term Investments	1.10M	405.00K	1.20M	3.35M	10.46M	14.63M
Total Debt	137.00K	238.00K	348.00K	481.00K	611.00K	1.07M
Total Liabilities	1.65M	2.42M	2.58M	2.27M	2.94M	3.06M
Stockholders Equity	8.09M	6.33M	7.32M	14.91M	23.89M	32.80M
Cash Flow
Free Cash Flow	-5.89M	-5.28M	-5.71M	-7.67M	-8.23M	-12.39M
Operating Cash Flow	-5.54M	-4.79M	-5.20M	-7.05M	-7.46M	-10.80M
Investing Cash Flow	-40.00K	-442.00K	-317.00K	-235.00K	-742.00K	3.39M
Financing Cash Flow	5.11M	4.45M	3.52M	100.00K	4.14M	14.69M

IGC Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.28, and below the 200-day MA of 0.34, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.88 is Neutral, neither overbought nor oversold. The STOCH value of 29.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IGC.

IGC Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELUT	51 Neutral	$43.98M	0.10	-225.83%	―	-14.92%	72.81%
IGC	47 Neutral	$27.69M	-5.18	-96.36%	―	-6.51%	58.31%
VRCA	47 Neutral	$108.40M	-2.74	252.30%	―	234.73%	81.16%
DYAI	46 Neutral	$29.03M	-5.15	-537.20%	―	-0.66%	-8.43%
PLUR	40 Underperform	$32.46M	-1.06	280.42%	―	121.74%	24.75%

IGC Pharma Corporate Events

IGC Pharma Secures New Debt Financing for Liquidity

On March 5, 2026, IGC Pharma, Inc. entered into a Securities Purchase Agreement with Vanquish Funding Group Inc., issuing a $353,050 promissory note, including a $46,050 original issue discount, for a purchase price of $307,000 maturing on February 28, 2027, with proceeds earmarked for general working capital. The note may be converted into common stock only upon an event of default at a 25% discount to the lowest trading price over the prior 10 trading days, subject to a 4.99% ownership cap for the holder and a 19.99% overall issuance cap absent shareholder approval, while the company also secured an additional approximately $219,000 loan from One Deck Capital, Inc. for working capital and general corporate purposes, collectively reinforcing its near-term liquidity through non-public, exempt financing structures.

The most recent analyst rating on (IGC) stock is a Hold with a $0.26 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.

IGC Pharma Announces Registered Direct Equity Offering Financing

On January 5, 2026, IGC Pharma, Inc. entered into a subscription agreement with a group of investors for a registered direct offering of 779,997 shares of common stock at $0.30 per share, raising approximately $234,000 in gross proceeds before expenses, with closing expected on or about the same date subject to customary conditions. The company plans to use the net proceeds for working capital and general corporate purposes, including funding its clinical development programs, R&D activities and other business initiatives, underscoring its need for continued financing to support ongoing operations and pipeline development.

The most recent analyst rating on (IGC) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.

IGC Pharma Adjusts Fiscal Year-End to December 31

On December 30, 2025, IGC Pharma, Inc. announced that its Board of Directors approved a change in the company’s fiscal year-end from March 31 to December 31, effective December 31, 2025. To accommodate this shift, the company plans to file an annual transition report covering a nine-month period from April 1, 2025, through December 31, 2025, a move that will align its reporting calendar more closely with the standard calendar year and may simplify financial reporting and comparability for investors and other stakeholders.

The most recent analyst rating on (IGC) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.

IGC Pharma Increases Authorized Shares to 600 Million

IGC Pharma, Inc. announced an amendment to its Articles of Incorporation to increase its authorized common stock from 150 million to 600 million shares, effective December 12, 2025. This decision, approved by stockholders on October 10, 2025, aims to enhance the company’s capital structure and potentially impact its market operations by expanding its capacity to issue more shares.

The most recent analyst rating on (IGC) stock is a Hold with a $0.34 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.